Form 4: ADC Therapeutics Director Peter Hug Receives Annual Equity Grant

ADC Therapeutics SA Director Peter Hug has been granted 40,000 restricted stock units (RSUs) as part of his annual compensation, aligning his interests with shareholders.

Summary

• Peter Hug, a Director of ADC Therapeutics SA (ADCT), acquired 40,000 common shares in the form of Restricted Stock Units (RSUs) on June 3, 2025.
• This grant represents the annual award under the Issuer's 2019 Equity Incentive Plan for his service as a Director.
• The RSUs were granted at a price of $0 per unit, indicating they are compensation.
• Following this transaction, Peter Hug beneficially owns a total of 222,644 common shares.
• The RSUs are subject to a one-year vesting period from the grant date, contingent upon Mr. Hug's continued service to the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. This is a routine and expected compensation event that aligns the director's interests with shareholders, which is generally viewed favorably. It does not indicate any negative operational or financial news.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Peter Hug aligns his financial interests directly with the long-term performance and shareholder value of ADC Therapeutics SA.
• This is a standard practice for director compensation, indicating a routine and expected part of corporate governance.

Risks

• The vesting of the 40,000 Restricted Stock Units is subject to Peter Hug's continued service to ADC Therapeutics SA for one year from the grant date, meaning the shares are not immediately owned outright.

Future Outlook

The 40,000 Restricted Stock Units granted to Director Peter Hug are expected to vest one year from the grant date, contingent upon his continued service to ADC Therapeutics SA.

Industry Context

The grant of Restricted Stock Units to a director is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to compensate board members and align their interests with long-term shareholder value. This transaction reflects a routine aspect of corporate governance and executive compensation.

Comparison to Industry Standards

• The practice of granting equity, such as Restricted Stock Units (RSUs), to non-executive directors is a standard compensation mechanism across global public companies, including those in the biotechnology sector like ADC Therapeutics SA.
• Companies such as Biogen Inc. (BIIB), Gilead Sciences, Inc. (GILD), and Amgen Inc. (AMGN) commonly utilize similar equity-based compensation plans for their directors to foster long-term alignment with shareholder interests.
• The vesting schedule of one year is also a typical period for annual director equity grants, ensuring continued commitment and service.

Related Party Transactions

• The grant of 40,000 Restricted Stock Units to Peter Hug, a Director of ADC Therapeutics SA, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Experience minor dilution from the issuance of new shares upon vesting, but benefit from the alignment of the director's interests with long-term company performance.
• Director (Peter Hug): Receives equity compensation for his service, incentivizing his continued contribution to the company's success.

Next Steps

• The 40,000 Restricted Stock Units are expected to vest on June 3, 2026, provided Peter Hug continues his service as a Director of ADC Therapeutics SA.

Key Dates

Keywords

ADC Therapeutics, ADCT, Peter Hug, Form 4, SEC filing, Restricted Stock Units, RSUs, equity grant, director compensation, insider transaction, beneficial ownership